Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterCorrespondence

Drs. Monsalve and Anaya reply

Diana M. Monsalve and Juan-Manuel Anaya
The Journal of Rheumatology January 2021, 48 (1) 149; DOI: https://doi.org/10.3899/jrheum.200670
Diana M. Monsalve
1Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan-Manuel Anaya
1Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: juan.anaya@urosario.edu.co
  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

We would like to thank Dr. Panchovska for her comments on our editorial1, which was motivated by the work of Sharma, et al2, who reported patients with sicca (100%) and other symptoms such as arthralgia (82%) and constitutional symptoms (43%) among others, in whom the presence of anti-Ro/SSA antibodies allowed a diagnosis of Sjögren syndrome (SS) despite a negative minor salivary gland (MSG) biopsy [i.e., focus score (FS) = 0].

The diagnosis of SS is based on the combination of symptoms (mainly sicca symptoms) and the presence of the autoimmune characteristics: activation of T cells (i.e., positive salivary gland biopsy) or B cells (i.e., presence of autoantibodies). However, not all the individuals presenting sicca symptoms have SS. No single test of oral or ocular involvement is sufficiently sensitive and specific to form a standard diagnosis of SS. Only the simultaneous positivity of various tests with the presence of subjective symptoms and serological abnormalities (anti-Ro/SSA and anti-La/SSB antibodies), and/or the presence of a score that is more than an FS on the MSG biopsy allow sufficient accuracy in the diagnosis of this disorder. In brief, a correct diagnosis is based on clinical suspicion, laboratory tests, and differential diagnosis.

In patients with negative MSG biopsy, the positivity of anti-Ro/SSA antibody is a key point based on the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria3. The sensitivity and specificity of these criteria reported in the original validation cohort was 96% (95% CI 92–98) and 95% (95% CI 92–97), respectively3. However, Tsuboi, et al4 reported that the current ACR/EULAR criteria have significantly higher sensitivity (95.4%) and lower specificity (72.1%) in comparison with the other past criteria. These results were confirmed by van Nimwegen, et al in a Dutch cohort5.

As mentioned by Dr. Panchovska6, anti-Ro/SSA antibodies are found not only in patients with SS but also in patients with other autoimmune diseases, as well as in healthy individuals. Clinical and immunological associations are different depending on the presence of anti-Ro52 or anti-Ro60 antibodies and the assay used for their detection7. Anti-Ro52 together with anti-Ro60 positivity is more likely to be associated with SS8. Isolated anti-Ro52 antibodies lack of specificity and sensitivity for SS diagnosis, being of particular interest in the diagnosis of inflammatory myositis or systemic sclerosis8,9. Isolated anti-Ro60 antibodies, although rare, are mainly associated with systemic lupus erythematosus8.

Although several genetics factors have been described to be associated to SS, including HLA alleles, so far they are not diagnostic tests10. Identification and evaluation of novel biomarkers will be useful to elucidate pathophysiology, classification of clinical subphenotypes, prediction of complications, and as diagnostic tools. For instance, antisalivary protein 1, anticarbonic anhydrase 6, and antiparotid secretory protein antibodies occur before anti-Ro/SSA or anti-La/SSB antibodies11. Sialic acid-binding immunoglobulin-like lectin 5 might be promising due to its association with severity of hyposalivation and ocular surface damage12. Alpha-enolase, cystatin S, and β2-microglobulin have been also suggested, but none of them have been clinically validated13,14,15.

REFERENCES

  1. 1.↵
    1. Monsalve DM,
    2. Anaya JM.
    With minor salivary gland biopsy in Sjogren syndrome, is a negative result possible? J Rheumatol 2020;47:310-2.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Sharma R,
    2. Chaudhari KS,
    3. Kurien BT,
    4. Grundahl K,
    5. Radfar L,
    6. Lewis DM, et al.
    Sjögren syndrome without focal lymphocytic infiltration of the salivary glands. J Rheumatol 2020;47:394-9.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Shiboski CH,
    2. Shiboski SC,
    3. Seror R,
    4. Criswell LA,
    5. Labetoulle M,
    6. Lietman TM, et al; International Sjögren’s Syndrome Criteria Working Group
    . 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome. Ann Rheum Dis 2017;76:9-16.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Tsuboi H,
    2. Hagiwara S,
    3. Asashima H,
    4. Takahashi H,
    5. Hirota T,
    6. Noma H, et al.
    Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjogren’s syndrome with other sets of criteria in Japanese patients. Ann Rheum Dis 2017;76:1980-5.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. van Nimwegen JF,
    2. van Ginkel MS,
    3. Arends S,
    4. Haacke EA,
    5. van der Vegt B,
    6. Sillevis Smitt-Kamminga N, et al.
    Validation of the ACR-EULAR criteria for primary Sjogren’s syndrome in a Dutch prospective diagnostic cohort. Rheumatology 2018;57:818-25.
    OpenUrl
  6. 6.↵
    1. Panchovska M.
    Questions from patients and doctors on negative minor salivary gland biopsy in Sjögren Syndrome. J Rheumatol 2021:48:149.
  7. 7.↵
    1. Pacheco Y,
    2. Monsalve DM,
    3. Acosta-Ampudia Y,
    4. Rojas C,
    5. Anaya JM,
    6. Ramirez-Santana C.
    Antinuclear autoantibodies: discordance among four different assays. Ann Rheum Dis 2020;79:e6.
    OpenUrlFREE Full Text
  8. 8.↵
    1. Robbins A,
    2. Hentzien M,
    3. Toquet S,
    4. Didier K,
    5. Servettaz A,
    6. Pham BN, et al.
    Diagnostic utility of separate anti-Ro60 and anti-Ro52/TRIM21 antibody detection in autoimmune diseases. Front Immunol 2019;10:444.
    OpenUrl
  9. 9.↵
    1. Zampeli E,
    2. Mavrommati M,
    3. Moutsopoulos HM,
    4. Skopouli FN.
    Anti-Ro52 and/or anti-Ro60 immune reactivity: autoantibody and disease associations. Clin Exp Rheumatol 2020 Feb 18 (Epub ahead of print).
  10. 10.↵
    1. Harris VM,
    2. Scofield RH,
    3. Sivils KL.
    Genetics in Sjogren’s syndrome: where we are and where we go. Clin Exp Rheumatol 2019;37 Suppl 118:234-9.
    OpenUrl
  11. 11.↵
    1. Martin-Nares E,
    2. Hernandez-Molina G.
    Novel autoantibodies in Sjogren’s syndrome: A comprehensive review. Autoimmun Rev 2019;18:192-8.
    OpenUrl
  12. 12.↵
    1. Lee J,
    2. Lee J,
    3. Baek S,
    4. Koh JH,
    5. Kim JW,
    6. Kim SY, et al.
    Soluble siglec-5 is a novel salivary biomarker for primary Sjogren’s syndrome. J Autoimmun 2019;100:114-9.
    OpenUrl
  13. 13.↵
    1. Hu S,
    2. Gao K,
    3. Pollard R,
    4. Arellano-Garcia M,
    5. Zhou H,
    6. Zhang L, et al.
    Preclinical validation of salivary biomarkers for primary Sjogren’s syndrome. Arthritis Care Res 2010;62:1633-8.
    OpenUrlCrossRef
  14. 14.↵
    1. Martini D,
    2. Gallo A,
    3. Vella S,
    4. Sernissi F,
    5. Cecchettini A,
    6. Luciano N, et al.
    Cystatin S-a candidate biomarker for severity of submandibular gland involvement in Sjogren’s syndrome. Rheumatology 2017;56:1031-8.
    OpenUrl
  15. 15.↵
    1. Riega-Torres J,
    2. Delgado-Garcia G,
    3. Salas-Alanis JC,
    4. Skinner-Taylor C,
    5. Perez-Barbosa L,
    6. Garza-Elizondo M, et al.
    Beta-2 microglobulin in whole unstimulated saliva can effectively distinguish between Sjogren’s syndrome and non-autoimmune sicca symptoms. Arch Rheumatol 2017;32:284-9.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 48, Issue 1
1 Jan 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Drs. Monsalve and Anaya reply
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Drs. Monsalve and Anaya reply
Diana M. Monsalve, Juan-Manuel Anaya
The Journal of Rheumatology Jan 2021, 48 (1) 149; DOI: 10.3899/jrheum.200670

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Drs. Monsalve and Anaya reply
Diana M. Monsalve, Juan-Manuel Anaya
The Journal of Rheumatology Jan 2021, 48 (1) 149; DOI: 10.3899/jrheum.200670
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Dr. Sugawara et al reply
  • Drs. Dai and Fan reply
  • Drs. Bessette and Kinch reply
Show more Correspondence

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire